RxDoctor Payments Data

Murad Kheetan, MD

Nephrology · Huntington, WVNPI 1326453952

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,061 of the $25,414 with a category attached, or 98.6%. Sanofi accounts for 98.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $25,061 and has fallen 99.8% since, to $56 in 2025. Among nephrology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,414in general payments, 2019–2025

Across 14 payments — averaging $1815.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$25K
  • AstraZeneca$159
  • Ardelyx, Inc.$71
  • Travere Therapeutics, Inc.$68
  • Vifor Pharma, Inc.$24
  • Otsuka America Pharmaceutical, Inc.$18
  • plus $13 from 1 others

What the payments were for

  • Grants$25,06199%
  • Food & beverage$2471%
  • Education$1050%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,414 in reported general payments places this provider in the 95th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$260,141
Medicare patients
549
Services billed
2,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide48$139,917
FarxigaDapagliflozin Propanediol87$89,913
JardianceEmpagliflozin41$40,488
KerendiaFinerenone25$24,034
EliquisApixaban12$10,565
Sevelamer Carbonate29$4,718
Potassium Citrate ErPotassium Citrate51$4,128
Losartan Potassium285$2,567
Torsemide77$2,089
Chlorthalidone134$1,459
Spironolactone113$1,216
Furosemide153$1,139
Calcitriol54$1,135
Allopurinol139$1,092
Carvedilol107$955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$159$89,91387 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →